Model Kengrexal - Cangrelor (Powder For Solution To Be Diluted For Injection/Perfusion)

Kengrexal, co-administered with acetylsalicylic acid (ASA), is indicated for the reduction of thrombotic cardiovascular events in adult patients with coronary artery disease having undergone a percutaneous coronary intervention (PCI), who have not received an oral P2Y12 receptor inhibitor prior to the intervention and in whom the oral route for such a treatment is not feasible or desirable.